CORZIDE Drug Patent Profile

When do Corzide patents expire, and what generic alternatives are available?

Corzide is a drug marketed by King Pharms Llc and is included in one NDA.

The generic ingredient in CORZIDE is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.

Summary for CORZIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	2
Drug Prices:	Drug price information for CORZIDE
DailyMed Link:	CORZIDE at DailyMed

See drug prices for CORZIDE

Recent Clinical Trials for CORZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mylan Pharmaceuticals	Phase 1

See all CORZIDE clinical trials

US Patents and Regulatory Information for CORZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983		DISCN	Yes	No
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983		DISCN	Yes	No

Expired US Patents for CORZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	3,935,267
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	3,982,021
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	3,982,021

International Patents for CORZIDE

See the table below for patents covering CORZIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	548978	PROCEDE DE PREPARATION DE NOUVEAUX COMPOSES 2,3-TRANSTETRAHYDRONAPHTYLOXYAMINOPROPANOL.
Germany	2258995
United Kingdom	1358722

CORZIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Corzide

Introduction

Corzide, a combination drug consisting of nadolol and bendroflumethiazide, is used to treat hypertension by lowering blood pressure. Understanding the market dynamics and financial trajectory of Corzide involves examining its indications, market position, competition, and economic factors influencing its development and sales.

Indications and Usage

Corzide is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events such as strokes and myocardial infarctions. It combines a nonselective beta-adrenergic blocking agent (nadolol) and a thiazide diuretic (bendroflumethiazide), making it a convenient option for patients who require multiple antihypertensive agents[1].

Market Position

In the antihypertensive market, Corzide is one of several combination therapies available. The market is diverse, with various combinations of ACE inhibitors, calcium channel blockers, beta blockers, and diuretics. Corzide's position is as a beta blocker-diuretic combination, which, while effective, may not be as favored as other combinations like ACE inhibitor-calcium channel blocker or ACE inhibitor-diuretic combinations, which have shown superior outcomes in reducing cardiovascular morbidity and mortality[4].

Competition

The antihypertensive market is highly competitive, with numerous combination drugs available. For instance, combinations like amlodipine/benazepril (Lotrel) and enalapril/hydrochlorothiazide (Vaseretic) are widely used and have established market presence. Corzide competes directly with other beta blocker-diuretic combinations such as atenolol/chlorthalidone (Tenoretic) and metoprolol/hydrochlorothiazide (Lopressor HCT)[4].

Economic Factors

Development Costs

The development of combination drugs like Corzide involves significant costs, including research, clinical trials, and regulatory approvals. These costs are typically high due to the complexity of combining two active ingredients and ensuring their safety and efficacy in a single formulation[3].

Pricing Strategy

The pricing of Corzide is influenced by its market position and competition. Generally, combination antihypertensive drugs are priced based on their component drugs and the convenience they offer. For Corzide, the monthly cost is around $71 for the 40/5 mg formulation, which is comparable to but sometimes higher than the cost of individual components or other combination therapies[4].

Revenue and Sales

The financial trajectory of Corzide is tied to its prescription rates and market demand. While specific revenue figures for Corzide are not publicly available, the overall antihypertensive market is substantial. The success of Corzide depends on its ability to capture a significant share of this market, which can be challenging given the competition.

Patient and Physician Preferences

Physician and patient preferences play a crucial role in the sales of Corzide. The drug's convenience as a single tablet can be a significant advantage, but it must also demonstrate comparable or superior efficacy and safety profiles to other available options. Educational campaigns and support programs can influence prescribing habits and patient adherence, which in turn affect sales[1].

Clinical and Regulatory Considerations

Clinical Trials

There are no controlled trials demonstrating risk reduction specifically with Corzide, which can impact its market appeal compared to drugs with robust clinical trial data. However, the benefits of its component drugs are well-documented, and Corzide is often prescribed based on the established efficacy of nadolol and bendroflumethiazide[1].

Regulatory Environment

The regulatory environment for antihypertensive drugs is stringent, with guidelines from bodies like the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) influencing treatment protocols. Compliance with these guidelines is crucial for maintaining market approval and physician trust[1].

Contraindications and Side Effects

Corzide has specific contraindications, such as bronchial asthma, sinus bradycardia, and overt cardiac failure, which can limit its use in certain patient populations. These limitations can affect its market reach and revenue potential[1].

Market Trends

Combination Therapy Trends

The trend in antihypertensive treatment is towards combination therapy to achieve better blood pressure control and reduce cardiovascular risk. Corzide benefits from this trend but must compete with other combination drugs that may offer additional benefits or fewer side effects[4].

Generic Competition

The antihypertensive market is subject to generic competition, which can significantly impact the sales of branded drugs like Corzide. As patents expire, generic versions of the component drugs or the combination itself can enter the market, reducing the revenue for the branded product[3].

Financial Projections

Given the competitive nature of the antihypertensive market and the lack of specific financial data on Corzide, precise financial projections are challenging. However, the overall market for antihypertensive drugs is large and growing, driven by increasing prevalence of hypertension and the need for effective treatments.

Key Takeaways

• Market Position: Corzide is a beta blocker-diuretic combination in a competitive antihypertensive market.
• Economic Factors: Development costs, pricing strategy, and competition influence its financial trajectory.
• Clinical and Regulatory Considerations: Lack of specific clinical trials and regulatory compliance are critical.
• Contraindications and Side Effects: Specific contraindications limit its use in certain patient populations.
• Market Trends: Combination therapy trends and generic competition are significant factors.

FAQs

What is Corzide used for?

Corzide is used for the treatment of hypertension to lower blood pressure and reduce the risk of fatal and nonfatal cardiovascular events.

What are the components of Corzide?

Corzide combines nadolol, a nonselective beta-adrenergic blocking agent, and bendroflumethiazide, a thiazide diuretic.

What are the contraindications for Corzide?

Corzide is contraindicated in patients with bronchial asthma, sinus bradycardia, greater than first-degree conduction block, cardiogenic shock, and overt cardiac failure.

How does Corzide compare to other antihypertensive combinations?

Corzide competes with other combination therapies like ACE inhibitor-calcium channel blocker and ACE inhibitor-diuretic combinations, which may offer superior outcomes in reducing cardiovascular morbidity and mortality.

What are the economic implications of Corzide's development and sales?

The development of Corzide involves significant costs, and its pricing is influenced by market competition and the convenience it offers as a combination drug.

Sources

1. Drugs.com: Corzide: Package Insert / Prescribing Information.
2. Corcept Therapeutics: Announces First Quarter Financial Results (not directly related to Corzide).
3. NBER: The Economics of Drug Development: Pricing and Innovation in a Changing Market.
4. AAFP: Managing Hypertension Using Combination Therapy.